Patents by Inventor Beibei Chen

Beibei Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12286442
    Abstract: This document provides methods and materials for increasing TFEB polypeptide levels. For example, compounds (e.g., organic compounds) having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, formulations containing compounds having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, methods for making compounds having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, methods for making formulations containing compounds having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, methods for increasing TFEB polypeptide levels within cells and/or within a nucleus of cells, and methods for treating mammals (e.g., humans) having a condition responsive to an increase in TFEB polypeptide levels are provided.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: April 29, 2025
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Beibei Chen, Toren Finkel, Yuan Liu
  • Publication number: 20240124410
    Abstract: Small molecule inhibitors that block the interaction between B-cell lymphoma 10 protein (BCL10) and mucosa- associated lymphoid tissue lymphoma translocation protein 1 (MALT1), thereby inhibiting both the protease and scaffolding activities of MALT1, and MALT1- dependent downstream signaling, including IL-6 and IL-10 secretion by B-cell lymphoma cells and IL-2 transcription and secretion by Jurkat T cells.
    Type: Application
    Filed: March 24, 2022
    Publication date: April 18, 2024
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, Regents of the University of Michigan
    Inventors: Peter C. Lucas, Linda M. McAllister, Heejae Kang, Beibei Chen, Lisa Maurer, Dong Hu, Jing Cheng, Linda Klei, Zaneta Nikolovska-Coleska
  • Publication number: 20240000806
    Abstract: This document provides compounds that can inhibit CB1 activity within a mammal (e.g., a human), as well as the methods of using such compounds for treating diseases, disorders, and conditions such as obesity, fear, metabolic-related disorders, diabetes, dyslipidaemia, and atherosclerosis.
    Type: Application
    Filed: November 19, 2021
    Publication date: January 4, 2024
    Inventors: Beibei Chen, Toren Finkel, Yuan Liu
  • Patent number: 11857550
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: January 2, 2024
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States Government as Represented By the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli
  • Publication number: 20230321086
    Abstract: This document provides compounds that are inhibitors of NAMPT activity, as well as the methods of using such compounds for treating diseases and conditions such as cancer, inflammatory conditions, autoimmune conditions, and conditions characterized by acute or sub-acute neuronal injury.
    Type: Application
    Filed: November 19, 2021
    Publication date: October 12, 2023
    Inventors: Beibei Chen, Toren Finkel, Yuan Liu
  • Publication number: 20230310424
    Abstract: This document provides compounds that can increase NAMPT activity, as well as the methods of using such compounds to treat diseases, disorders, and conditions such as traumatic nerve and/or brain injuries, chemotherapeutic-induced or diabetic neuropathies, and neurodegenerative diseases.
    Type: Application
    Filed: November 19, 2021
    Publication date: October 5, 2023
    Inventors: Beibei Chen, Toren Finkel, Yuan Liu
  • Publication number: 20230203023
    Abstract: Various salt forms of Compound I and Compound II represented by the following structural formulae, and their corresponding pharmaceutical compositions, are disclosed. (I), (II) Particular single crystalline forms of 1:1 Compound I tris salt, 1:1 Compound II tris salt, and 1:1 Compound II citrate salt are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease in a subject.
    Type: Application
    Filed: May 26, 2021
    Publication date: June 29, 2023
    Inventors: Meng Jiang, Beibei Chen, Xudong Wei, Wenge Zhong
  • Patent number: 11673853
    Abstract: Described herein are compounds that disrupt the interaction between Fbxo48 and phosphorylated-AMPK.
    Type: Grant
    Filed: May 6, 2021
    Date of Patent: June 13, 2023
    Assignees: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, The United States as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli, Yuan Liu
  • Publication number: 20230041576
    Abstract: This document provides compounds that are inhibitors of NF-?B activity, as well as the methods of using such compounds for treating diseases and conditions such as cancer, inflammatory conditions, or autoimmune diseases.
    Type: Application
    Filed: November 20, 2020
    Publication date: February 9, 2023
    Inventors: Beibei Chen, Toren Finkel, Yuan Liu
  • Publication number: 20220340533
    Abstract: This document provides methods and materials for increasing the level of phosphorylated AMPK. For example, compounds (e.g., organic compounds) having the ability to increase the level of phosphorylated AMPK within cells, formulations containing compounds having the ability to increase the level of phosphorylated AMPK within cells, methods for making compounds having the ability to increase the level of phosphorylated AMPK within cells, methods for making formulations containing compounds having the ability to increase the level of phosphorylated AMPK within cells, methods for increasing the level of phosphorylated AMPK within cells, and methods for treating mammals (e.g., humans) having a condition responsive to an increase in the level of phosphorylated AMPK are provided.
    Type: Application
    Filed: September 9, 2020
    Publication date: October 27, 2022
    Inventors: Beibei Chen, Toren Finkel, Yuan Liu
  • Publication number: 20220204484
    Abstract: A method for treating a neurodegenerative disease or an inflammatory disorder in a subject, comprising administering to the subject in need thereof, a compound, or a pharmaceutically acceptable salt thereof, of formula II: wherein each of R3-R7 is independently H, halogen, optionally-substituted alkyl, amino, alkoxy or hydroxy; R8 is an optionally-substituted heterocycloalkyl; and a is 0 to 3.
    Type: Application
    Filed: December 13, 2021
    Publication date: June 30, 2022
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Rama K. Mallampalli, Beibei Chen, Charleen T. Chu, Yuan Liu
  • Publication number: 20220169632
    Abstract: This document provides methods and materials for increasing or maintaining NMNAT2 polypeptide levels within cells. For example, compounds (e.g., organic compounds) having the ability to increase or maintain NMNAT2 polypeptide levels within cells, formulations containing compounds having the ability to increase or maintain NMNAT2 polypeptide levels within cells, methods for making compounds having the ability to increase or maintain NMNAT2 polypeptide levels within cells, methods for making formulations containing compounds having the ability to increase or maintain NMNAT2 polypeptide levels within cells, methods for increasing or maintain NMNAT2 polypeptide levels within cells, and methods for treating mammals (e.g., humans) having a condition responsive to an increase in NMNAT2 polypeptide levels are provided (or for preventing said condition).
    Type: Application
    Filed: February 21, 2020
    Publication date: June 2, 2022
    Inventors: Beibei Chen, Toren Finkel, Yuan Liu
  • Publication number: 20220153685
    Abstract: Described herein are compounds that disrupt the interaction between Fbxo48 and phosphorylated-AMPK.
    Type: Application
    Filed: May 6, 2021
    Publication date: May 19, 2022
    Inventors: Beibei Chen, Rama K. Mallampalli, Yuan Liu
  • Publication number: 20220112218
    Abstract: This document provides methods and materials for increasing TFEB polypeptide levels. For example, compounds (e.g., organic compounds) having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, formulations containing compounds having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, methods for making compounds having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, methods for making formulations containing compounds having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, methods for increasing TFEB polypeptide levels within cells and/or within a nucleus of cells, and methods for treating mammals (e.g., humans) having a condition responsive to an increase in TFEB polypeptide levels are provided.
    Type: Application
    Filed: January 3, 2020
    Publication date: April 14, 2022
    Inventors: Beibei Chen, Toren Finkel, Yuan Liu
  • Patent number: 11242339
    Abstract: A method for treating a neurodegenerative disease or an inflammatory disorder in a subject, comprising administering to the subject in need thereof, a compound, or a pharmaceutically acceptable salt thereof, of formula II: wherein each of R3-R7 is independently H, halogen, optionally-substituted alkyl, amino, alkoxy or hydroxy; R8 is an optionally-substituted heterocycloalkyl; and a is 0 to 3.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: February 8, 2022
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Rama K. Mallampalli, Beibei Chen, Charleen T. Chu, Yuan Liu
  • Publication number: 20210315895
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.
    Type: Application
    Filed: November 19, 2020
    Publication date: October 14, 2021
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli
  • Patent number: 11072606
    Abstract: A compound of Formula II, or a salt, ester, solvate, hydrate or prodrug thereof: where: X1 is a branched or unbranched C1-10 alkyl, (CH2)s—NH—(CH2)t, (CH2)s—O—(CH2)t, or (CH2)s—C(NH2)—(CH2)v—NH—(CH2)t, where s, t and v are each, independently an integer from 1 to 5; A and B are each, independently, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl, each optionally substituted with 1, 2 or 3 independently selected Rg groups; C and D are each, independently, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl-C1-6 alkyl, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl, each optionally substituted with 1, 2 or 3 independently selected Rg groups; each Rg is, independently, halogen, C1-6 alkyl, C1-6 haloalkyl, hydroxyl, C1-6 alkoxy, C1-6 haloalkoxy, amino, C1-6alkylamino, or di-C1-6alkylamino; and n1 and p1 are each, independently, integers from 1 to 10.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: July 27, 2021
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli
  • Patent number: 11040935
    Abstract: Described herein are compounds that disrupt the interaction between Fbxo48 and phosphorylated-AMPK.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: June 22, 2021
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli, Yuan Liu
  • Patent number: 10968183
    Abstract: Novel compounds are disclosed along with methods of inhibiting the TGF? pathway and methods of treating Idiopathic Pulmonary Fibrosis (IPF) using such compounds.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: April 6, 2021
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventor: Beibei Chen
  • Patent number: D922463
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: June 15, 2021
    Assignee: ABB Schweiz AG
    Inventors: Bin Liu, Junjie Hu, Zhen Shi, Jiabei Shi, Xingjie Li, Wenxuan Wu, Yusheng Cai, Beibei Chen